Polyglutamine expanded huntingtin dramatically alters the genome-wide binding of HSF1

Journal of Huntington's Disease

Volumn 1, Issue 1, 2012, Pages 33-45

  Riva, Laura ^a,d   Koeva, Martina ^a,b   Yildirim, Ferah ^a   Pirhaji, Leila ^a   Dinesh, Deepika ^a   Mazor, Tali ^a   Duennwald, Martin L ^c   Fraenkel, Ernest ^a  

^a Massachusetts Institute of Technology Cambridge   (United States)

^b WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH   (United States)

^c BOSTON BIOMEDICAL RESEARCH INSTITUTE   (United States)

^d ISTITUTO ITALIANO DI TECNOLOGIA   (Italy)

Author keywords

cDNA microarrays; chromatin immunoprecipitation; deep sequencing; heat shock transcription factor; heat shock response; Huntington disease

Indexed keywords

GUANOSINE TRIPHOSPHATASE; HEAT SHOCK TRANSCRIPTION FACTOR 1; HUNTINGTIN; POLYGLUTAMINE; DNA BINDING PROTEIN; HEAT SHOCK TRANSCRIPTION FACTOR; HTT PROTEIN, HUMAN; NERVE PROTEIN; PEPTIDE; TRANSCRIPTION FACTOR;

ANIMAL TISSUE; ARTICLE; BINDING SITE; CELL VIABILITY; CHROMATIN IMMUNOPRECIPITATION; ENZYME ACTIVITY; FLUORESCENCE ACTIVATED CELL SORTING; GENE SEQUENCE; HEAT SHOCK; MOUSE; NEUROPROTECTION; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN HOMEOSTASIS; STRESS; WILD TYPE; ANIMAL; CELL LINE; CHEMISTRY; DNA MICROARRAY; DNA SEQUENCE; GENETICS; GENOMICS; HIGH THROUGHPUT SEQUENCING; HUMAN; METABOLISM; MUTATION;

ANIMALS; CELL LINE; CHROMATIN IMMUNOPRECIPITATION; DNA-BINDING PROTEINS; GENOMICS; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MICE; MUTATION; NERVE TISSUE PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PEPTIDES; SEQUENCE ANALYSIS, DNA; TRANSCRIPTION FACTORS;

EID: 84880757782     PISSN: 18796397     EISSN: 18796400     Source Type: Journal    
DOI: 10.3233/JHD-2012-120020     Document Type: Article

References (60)

1. Anovel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group. Cell. 1993;72(6):971-83.
2. MacDonald ME, et al. Huntington's disease. Neuromolecular Med. 2003;4(1-2):7-20.
3. Voisine C, Pedersen JS, Morimoto RI. Chaperone networks: Tipping the balance in protein folding diseases. Neurobiol Dis. 2010;40(1):12-20.
4. Fujikake N, et al. Heat shock transcription factor 1-activating compounds suppress polyglutamine-induced neurodegeneration through induction of multiple molecular chaperones. J Biol Chem. 2008;283(38):26188-97.
5. Wang J, et al. Reversal of a full-length mutant huntingtin neuronal cell phenotype by chemical inhibitors of polyglutaminemediated aggregation. BMC Neurosci. 2005;6:1.
6. Akerfelt M, et al. Heat shock factors at a crossroad between stress and development. Ann N Y Acad Sci. 2007;1113: 15-27. (Pubitemid 350015004)
7. Fujimoto M, et al. Active HSF1 significantly suppresses polyglutamine aggregate formation in cellular and mouse models. J Biol Chem. 2005;280(41):34908-16. (Pubitemid 41504625)
8. Westerheide SD, Morimoto RI. Heat shock response modulators as therapeutic tools for diseases of protein conformation. J Biol Chem. 2005;280(39):33097-100. (Pubitemid 41397104)
9. Zhang YQ, Sarge KD. Celastrol inhibits polyglutamine aggregation and toxicity though induction of the heat shock response. J Mol Med (Berl). 2007;85(12):1421-8. (Pubitemid 350234097)
10. Trott A, et al. Activation of heat shock and antioxidant responses by the natural product celastrol: Transcriptional signatures of a thiol-targeted molecule. Mol Biol Cell. 2008;19(3):1104-12. (Pubitemid 351481823)
11. Sittler A, et al. Geldanamycin activates a heat shock response and inhibits huntingtin aggregation in a cell culture model of Huntington's disease. HumMol Genet. 2001;10(12):1307-15. (Pubitemid 32600484)
12. Neef DW, Jaeger AM, Thiele DJ. Heat shock transcription factor 1 as a therapeutic target in neurodegenerative diseases. Nat Rev Drug Discov. 2011;10(12):930-44.
13. Neef DW, Turski ML, Thiele DJ. Modulation of heat shock transcription factor 1 as a therapeutic target for small molecule intervention in neurodegenerative disease. PLoS Biol. 2010;8(1):e1000291.
14. Anckar J, Sistonen L. Heat shock factor 1 as a coordinator of stress and developmental pathways. Adv Exp Med Biol. 2007;594:78-88.
15. Hahn JS, et al. Genome-wide analysis of the biology of stress responses through heat shock transcription factor. Mol Cell Biol. 2004;24(12):5249-56.
16. Birch-Machin I, et al. Genomic analysis of heat-shock factor targets in Drosophila. Genome Biol. 2005;6(7):R63.
17. Page TJ, et al. Genome-wide analysis of human HSF1 signaling reveals a transcriptional program linked to cellular adaptation and survival. Mol Biosyst. 2006;2(12):627-39. (Pubitemid 44772306)
18. Homma S, et al. Demyelination, astrogliosis, and accumulation of ubiquitinated proteins, hallmarks of CNS disease in hsf1-deficient mice. J Neurosci. 2007;27(30):7974-86. (Pubitemid 47173325)
19. Dai C, et al. Heat shock factor 1 is a powerful multifaceted modifier of carcinogenesis. Cell. 2007;130(6):1005-18. (Pubitemid 47410269)
20. Trettel F, et al. Dominant phenotypes produced by the HD mutation in STHdh(Q111) striatal cells. Hum Mol Genet. 2000;9(19):2799-809.
21. Labbadia J, et al. Altered chromatin architecture underlies progressive impairment of the heat shock response in mouse models of Huntington disease. J Clin Invest. 2011;121(8): 3306-19.
22. Trinklein ND, et al. The role of heat shock transcription factor 1 in the genome-wide regulation of the mammalian heat shock response. Mol Biol Cell. 2004;15(3):1254-61. (Pubitemid 38316232)
23. Bano D, et al. Neurodegenerative processes in Huntington's disease. Cell Death Dis. 2011;2:e228.
24. Li XJ, Li S. Proteasomal dysfunction in aging and Huntington disease. Neurobiol Dis. 2011;43(1):4-8.
25. Moore A, et al. Simultaneous measurement of cell cycle and apoptotic cell death. Methods Cell Biol. 1998;57:265-78. (Pubitemid 128787445)
26. Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009;4(1):44-57.
27. Huang da W, Sherman BT, Lempicki RA. Bioinformatics enrichment tools: Paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res. 2009;37(1):1-13.
28. Sadri-Vakili G, et al. Histones associated with downregulated genes are hypo-acetylated in Huntington's disease models. Hum Mol Genet. 2007;16(11):1293-306. (Pubitemid 47055125)
29. Lee JM, et al. Unbiased gene expression analysis implicates the huntingtin polyglutamine tract in extra-mitochondrial energy metabolism. PLoS Genet. 2007;3(8):e135.
30. Lin CH, et al. Neurological abnormalities in a knock-in mouse model of Huntington's disease. Hum Mol Genet. 2001;10(2):137-44.
31. DiProspero NA, et al. Early changes in Huntington's disease patient brains involve alterations in cytoskeletal and synaptic elements. J Neurocytol. 2004;33(5):517-33. (Pubitemid 40768575)
32. Zabel C, et al. A large number of protein expression changes occur early in life and precede phenotype onset in a mouse model for huntington disease. Mol Cell Proteomics. 2009; 8(4):720-34.
33. Kaltenbach LS, et al. Huntingtin interacting proteins are genetic modifiers of neurodegeneration. PLoS Genet. 2007;3(5):e82.
34. Munsie L, et al. Mutant huntingtin causes defective actin remodeling during stress: Defining a new role for transglutaminase 2 in neurodegenerative disease. Hum Mol Genet. 2011;20(10):1937-51.
35. Trushina E, et al. Mutant huntingtin impairs axonal trafficking in mammalian neurons in vivo and in vitro. Mol Cell Biol. 2004;24(18):8195-209. (Pubitemid 39167467)
36. Gauthier LR, et al. Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules. Cell. 2004;118(1): 127-38. (Pubitemid 38902819)
37. Kuhn A, et al. Mutant huntingtin's effects on striatal gene expression in mice recapitulate changes observed in human Huntington's disease brain and do not differ with mutant huntingtin length or wild-type huntingtin dosage. HumMol Genet. 2007;16(15):1845-61. (Pubitemid 47244533)
38. Hoffner G, Kahlem P, Djian P. Perinuclear localization of huntingtin as a consequence of its binding to microtubules through an interaction with beta-tubulin: Relevance to Huntington's disease. J Cell Sci. 2002;115(Pt 5):941-8. (Pubitemid 34257379)
39. Tukamoto T, et al. Huntington's disease gene product, huntingtin, associates with microtubules in vitro. Brain Res Mol Brain Res. 1997;51(1-2):8-14. (Pubitemid 27504026)
40. Caviston JP, et al. Huntingtin facilitates dynein/dynactinmediated vesicle transport. Proc Natl Acad Sci U S A. 2007; 104(24):10045-50. (Pubitemid 47175260)
41. Liu Q, et al. Neuronal LRP1 knockout in adult mice leads to impaired brain lipid metabolism and progressive, age-dependent synapse loss and neurodegeneration. J neurosci. 2010;30(50):17068-17078.
42. Li X, et al. Mutant huntingtin impairs vesicle formation from recycling endosomes by interfering with Rab11 activity. Mol Cell Biol. 2009;29(22):6106-16.
43. Thomas E, et al. In vivo cell-autonomous transcriptional abnormalities revealed in mice expressing mutant huntingtin in striatal but not cortical neurons. Hum Mol Genet. 2011;20(6):1049-60.
44. Chaturvedi RK, et al. Impaired PGC-1alpha function in muscle in Huntington's disease. Hum Mol Genet. 2009; 18(16):3048-65.
45. Bishop-Bailey D, Bystrom J. Emerging roles of peroxisome proliferator-activated receptor-beta/delta in inflammation. Pharmacol Ther. 2009;124(2):141-50.
46. Bence NF, Sampat RM, Kopito RR. Impairment of the ubiquitin-proteasome system by protein aggregation. Science. 2001;292(5521):1552-5. (Pubitemid 32493425)
47. Bennett EJ, et al. Global impairment of the ubiquitinproteasome system by nuclear or cytoplasmic protein aggregates precedes inclusion body formation. Mol Cell. 2005; 17(3):351-65. (Pubitemid 40193307)
48. Bennett EJ, et al. Global changes to the ubiquitin system in Huntington's disease. Nature. 2007;448(7154):704-8. (Pubitemid 47236860)
49. Diaz-Hernandez M, et al. Neuronal induction of the immunoproteasome in Huntington's disease. J Neurosci. 2003;23(37):11653-61. (Pubitemid 38021292)
50. Zemskov EA, Nukina N, Impaired degradation of PKCalpha by proteasome in a cellular model of Huntington's disease. Neuroreport. 2003;14(11):1435-8. (Pubitemid 37083123)
51. Fuchs M, et al. Identification of the key structural motifs involved in HspB8/HspB6-Bag3 interaction. Biochem J. 2010;425(1):245-55.
52. Irizarry RA, et al. Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res. 2003;31(4):e15.
53. Smyth GK, Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol. 2004;3:Article3.
54. Trinklein ND, et al. Transcriptional regulation and binding of heat shock factor 1 and heat shock factor 2 to 32 human heat shock genes during thermal stress and differentiation. Cell Stress Chaperones. 2004;9(1):21-8. (Pubitemid 38429072)
55. MacIsaac KD, et al. A quantitative model of transcriptional regulation reveals the influence of binding location on expression. PLoS Comput Biol. 2010;6(4):e1000773.
56. Zhang Y, et al. Model-based analysis of ChIP-Seq (MACS). Genome Biol. 2008;9(9):R137.
57. Kuhn RM, et al. The UCSC Genome Browser Database: Update 2009. Nucleic Acids Res. 2009;37(Database issue): D755-61.
58. Macisaac KD, et al. A hypothesis-based approach for identifying the binding specificity of regulatory proteins from chromatin immunoprecipitation data. Bioinformatics. 2006; 22(4):423-9.
59. Hodges A, et al. Regional and cellular gene expression changes in human Huntington's disease brain. Hum Mol Genet. 2006;15(6):965-77. (Pubitemid 43338237)
60. Sayers EW, et al. Database resources of the National Center for Biotechnology Information. Nucleic Acids Res. 2010;39(Database issue):D38-51.